Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Interleukin-2 in Autism Spectrum Disorders
NCT07589842Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Primary completion
- Nov 2028
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aldesleukin in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in Tregs at Day 8. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
aldesleukin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07589842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589842.